BRIEF published on 03/20/2026 at 13:05, 3 months 12 days ago ReproNovo Appoints Mark Altmeyer as Chairman of the Board Biopharmaceutical Fertility Leadership ReproNovo Mark Altmeyer
BRIEF published on 03/20/2026 at 13:05, 3 months 12 days ago ReproNovo nomme Mark Altmeyer président du conseil d'administration Biopharmaceutique Direction ReproNovo Mark Altmeyer Fécondité
PRESS RELEASE published on 03/20/2026 at 13:00, 3 months 12 days ago REPRONOVO APPOINTS MARK ALTMEYER AS CHAIRMAN OF THE BOARD ReproNovo appoints Mark Altmeyer as Chairman of the Board. Altmeyer brings 35+ years of biopharma leadership experience across multiple therapeutic areas Chairman Fertility Biopharma ReproNovo Mark Altmeyer
BRIEF published on 09/30/2025 at 07:05, 9 months 1 day ago ReproNovo Gains Approval for RPN-001 Clinical Trial in China Clinical Trial China Approval ReproNovo Reproductive Medicine RPN-001
BRIEF published on 09/30/2025 at 07:05, 9 months 1 day ago ReproNovo obtient l'approbation pour l'essai clinique RPN-001 en Chine Essai Clinique ReproNovo RPN-001 Approbation De La Chine Médecine De La Reproduction
PRESS RELEASE published on 09/30/2025 at 07:00, 9 months 1 day ago ReproNovo Announces Clinical Trial Approval Notice for RPN-001 in China ReproNovo receives approval for RPN-001 Phase 1 trial in China from NMPA, a key step in global development for male infertility treatment. Company expanding clinical programs in the U.S. and China China Male Infertility Clinical Trial ReproNovo RPN-001
BRIEF published on 07/01/2025 at 07:05, 1 year ago ReproNovo Initiates Phase 2 Trial for Male Infertility Drug in the U.S. Male Infertility Phase 2 Trial ReproNovo RPN-001 Low Testosterone
BRIEF published on 07/01/2025 at 07:05, 1 year ago ReproNovo lance un essai de phase 2 pour un médicament contre l'infertilité masculine aux États-Unis Essai De Phase 2 ReproNovo RPN-001 Infertilité Masculine Faible Taux De Testostérone
PRESS RELEASE published on 07/01/2025 at 07:00, 1 year ago REPRONOVO ANNOUNCES FIRST PARTICIPANT INCLUDED IN U.S. PHASE 2 TRIAL OF RPN-001 FOR MALE INFERTILITY ReproNovo announces first participant in U.S. Phase 2 trial of RPN-001 for male infertility, aiming to develop oral therapy for low testosterone men with impaired semen quality Male Infertility Phase 2 Trial ReproNovo RPN-001 Aromatase Inhibitor
BRIEF published on 05/21/2025 at 07:05, 1 year 1 month ago ReproNovo Secures $65 Million for Phase 2 Trials in Reproductive Health Innovation Clinical Trials Series A Financing Reproductive Health ReproNovo
Published on 07/01/2026 at 17:00, 3 hours 4 minutes ago Notification of Relevant Change to Significant Shareholder
Published on 07/01/2026 at 14:30, 5 hours 34 minutes ago AIAI Holdings' MediGuide Launches Digital Platform
Published on 07/01/2026 at 13:30, 6 hours 34 minutes ago Sidney Resources Corporation Appoints Former Idaho Governor C.L. "Butch" Otter as Chairman of the Board
Published on 07/01/2026 at 13:00, 7 hours 4 minutes ago Fox River Issues Shares Pursuant to Exploration Agreement in Connection with Impending Arrangement
Published on 07/01/2026 at 03:15, 16 hours 49 minutes ago GLG Life Tech Corporation Announces 2026 AGM Voting Results
Published on 07/01/2026 at 19:00, 1 hour 4 minutes ago PATRIMOINE ET COMMERCE: INFORMATIONS RELATIVES AU NOMBRE TOTAL DE DROITS DE VOTE ET AU NOMBRE D’ACTIONS COMPOSANT LE CAPITAL SOCIAL AU TITRE DE L’ARTICLE 223-16 DU REGLEMENT GENERAL DE L'AMF
Published on 07/01/2026 at 19:00, 1 hour 4 minutes ago OLB strengthens its leadership team to drive the next phase of growth
Published on 07/01/2026 at 18:55, 1 hour 9 minutes ago OLB Ensures Leadership Continuity Following Management Board Changes / Christophe Jéhan assumes responsibilities for Marc Ampaw’s business areas on interim basis
Published on 07/01/2026 at 18:29, 1 hour 35 minutes ago Aperam Update on Q2 2026 market & financial trends
Published on 07/01/2026 at 18:29, 1 hour 35 minutes ago Aperam Update on Q2 2026 market & financial trends
Published on 07/01/2026 at 19:40, 23 minutes ago Initiation de couverture du titre Solocal par Portzamparc
Published on 07/01/2026 at 18:26, 1 hour 37 minutes ago Modula renews its confidence in AMA with a four-year agreement integrating XpertEye’s new AI-powered features
Published on 07/01/2026 at 18:26, 1 hour 37 minutes ago Modula renouvelle sa confiance à AMA avec un contrat de quatre ans intégrant les nouvelles fonctionnalités IA d’XpertEye
Published on 07/01/2026 at 18:01, 2 hours 3 minutes ago Covivio Hotels - Informations relatives au nombre total de droits de vote et d’actions composant le capital social
